الفهرس | Only 14 pages are availabe for public view |
Abstract In the present study 4 hae.oetatio parameters were investigated in SO women receiving Gynera pille monthly for 6 months for birth control. All WOman were clinically h8althy, in the reproductive ag~, ~exually active, non lactating, have at leBst one normal menBtrual cycle B~nce terminat10n of there Ift~t pregnancy, must rely exclusively upon pills c.~ the’ onl::ymethod of contr6ception t.hrough t.he courae of lIt.udy and the lHat pregnancy tar~inated at lea~t.42 daya prio~ to admes~ion t.o the study. TO study the ri6k of venDue thromboeie in this group the following parameters were a6~e~sad entithrombin Ill, platelet count, bleeding time and clotting time. The reoultB obtained aftor 3 and 6 months of UBe of Gynera llIiI:rtI compared with the pretreatment ValUl’lB and the tollowinq re5ultg _~& reportQd. 1- No significant change WI1l.IIl dBtected in ant~throl’lbin III lE1VE11s aftllir 3 and 6 mcnthM of use of Gyn8:r1l.. 2- .No siqnific.!l.nctha.n,.’_!!8’ det.ected i’n platelet count after 3 and 6 months of use of Gynera. 3- Mo significant change W!aB detected in bleeding time after 3 and 6 month!> of use of Gynera. 4- No 15iqnif ic.ant change W8S detected in c~o’t.tinqtime after 3 and 6 months of use of Gynera. The eV61uated lo£luences of u~e 9f Gynera on plasma antithrombin lIl, platelet count, bleeding time and clotting time proved their relative safety regarding the risk of thromboslB. Howev9r, the risk of thro.bo~i8 can not be ruled out because the markers applied do not H~~e88 the multiple key variables which regulate coagulation and fibrinolyBi$. |